4.47k followers • 28 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks that were removed from most watchlists by Yahoo Finance Users. This list is generated daily and limited to the top 30 stocks that meet the criteria.
Curated by Yahoo Finance
Follow this list to discover and track stocks that were removed from most watchlists by Yahoo Finance Users. This list is generated daily and limited to the top 30 stocks that meet the criteria.
Background
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.
How are these weighted?The stocks in this watchlist are weighted equally.
Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
---|---|---|---|---|
Most Removed from Watchlists | - | - | - | - |
^GSPC | -0.04% | +2.42% | +23.76% | +5740.43% |
Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
---|
Wells Fargo (WFC) fired over a dozen employees over allegedly faking keyboard strokes and "mouse jigglers" to appear as if they were working, according to reports. Yahoo Finance's Morning Brief team discusses the employee sentiment around work-from-home and hybrid set ups as more companies push for a return to office mandate. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
The board of Best Buy Co., Inc. ( NYSE:BBY ) has announced that it will pay a dividend on the 11th of July, with...
WILMINGTON, Del., June 16, 2024--Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and showed a favorable trend in overall survival (OS) compared to standard-of-care chemoimmunotherapy (bendamustine plus rituximab) in previously untreated patients with mantle cell lymphoma (MCL).